Acute myeloid leukemia with isocitrate dehydrogenase-1 (IDH1) mutation

Acute myeloid leukemia with isocitrate dehydrogenase-1 (IDH1) mutation is an aggressive hematologic malignancy characterized by the clonal proliferation and accumulation of immature myeloid precursors in the bone marrow and peripheral blood Pathophysiologically, the mutated enzyme converts alpha-ketoglutarate into the oncometabolite D-2-hydroxyglutarate (2-HG), causing DNA and histone hypermethylation that arrests normal myeloid cell differentiation and promotes leukemogenesis Consequently, pati...

Acute myeloid leukemia with isocitrate dehydrogenase-1 (IDH1) mutation is an aggressive hematologic malignancy characterized by the clonal proliferation and accumulation of immature myeloid precursors in the bone marrow and peripheral blood Pathophysiologically, the mutated enzyme converts alpha-ketoglutarate into the oncometabolite D-2-hydroxyglutarate (2-HG), causing DNA and histone hypermethylation that arrests normal myeloid cell differentiation and promotes leukemogenesis Consequently, pati...

This molecularly defined subtype, observed primarily in adult patients, is driven by neomorphic somatic mutations in the cytosolic enzyme IDH1, most commonly at residue R132

This molecularly defined subtype, observed primarily in adult patients, is driven by neomorphic somatic mutations in the cytosolic enzyme IDH1, most commonly at residue R132

Pathophysiologically, the mutated enzyme converts alpha-ketoglutarate into the oncometabolite D-2-hydroxyglutarate (2-HG), causing DNA and histone hypermethylation that arrests normal myeloid cell differentiation and promotes leukemogenesis